{ "items": [ "\n\n
\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n19 July 2017
\n \n \n \nAn existing malaria rapid diagnostic test (RDT) can be adapted to predict the delayed anaemia that can complicate severe malaria in patients treated with artemisinin-based antimalarial drugs
\n \n\n \n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n14 July 2017
\n \n \n \nResearchers from Oxford University Clinical Research Unit in Vietnam have shown that amphotericin B is more effective than itraconazole for the initial treatment of talaromycosis in HIV patients.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n19 June 2017
\n \n \n \nIt has been maintained for decades that quinine is the safest drug for treatment of malaria in the first trimester of pregnancy. In the largest analysis of data from Thailand and Africa, artemisinins are reported to be at least as safe as quinine. This will simplify treatment protocols worldwide.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n26 May 2017
\n \n \n \nLast year PLOS articles received nearly 30 million downloads, of which Professor horby's article Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial was in the top 50 most downloaded.
\n \n\n \n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n5 April 2017
\n \n \n \nIn a guest blog, Professor Stephen Baker explains the importance of monitoring the emergence of infectious diseases in Asia. Zoonotic diseases that pass from animal to human are an international public health problem regardless of location, but in lower-income countries the opportunities for such pathogens to enter the food chain are amplified.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n3 February 2017
\n \n \n \nA lineage of multidrug resistant P. falciparum malaria has widely spread and is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for the main falciparum malaria medicines, artemisinin combination therapies (ACTs)
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n18 January 2017
\n \n \n \nIn the largest study of its kind, a team of researchers led by MORU and WWARN in Bangkok developed a pharmacokinetic model that enabled a revised dose regimen to safely treat all malaria patients including young children with dihydroartemisinin-piperaquine (DP), a widely used antimalarial and a first-line treatment against malaria recommended by the World Health Organization (WHO).
\n \n\n \n \n\n \n\n \n \n \n \n LOMWRU\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n14 December 2016
\n \n \n \nProf Paul Newton, Director of LOMWRU and Head of the Medicine Quality Group at the Infectious Diseases Data Observatory IDDO, explains the history of falsified medicines and highlights what needs to be done to avert a problem that threatens us all.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n18 October 2016
\n \n \n \nTraining local Karen and Burman women as skilled birth attendants in refugee settings resulted in no adverse perinatal outcomes and many positive outcomes such as a drop in stillbirths and infant deaths and more babies being born in clinics rather than at home, says a new study published in the scientific journal PLOS ONE.
\n \n\n \n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n3 October 2016
\n \n \n \nA study by the international Global Burden of Disease Study (GBD) collaboration (which includes researchers from OUCRU), published in The Lancet, analyzed each country\u2019s progress toward achieving the United Nation\u2019s health-related Sustainable Development Goals (SDG) targets by creating an overall SDG Index score. Countries were then ranked by their scores to show which nations are closest to achieving the targets, and Vietnam stands out as having achieved significant progress.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n14 September 2016
\n \n \n \nMultidrug-resistant bacterial infections cause more than 19,000 excess deaths a year in Thailand alone, according to a study published today in eLife Sciences Publications. In a first for Thailand, the study systematically examined microbiology laboratory and hospital databases from nine public hospitals in Northeast Thailand and compared them to Thailand\u2019s national death registry to estimate that 19,122 deaths in Thailand in 2010 were excess deaths caused by multidrug-resistant bacterial infections.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n28 June 2016
\n \n \n \nThe rapid decline in effectiveness of a widely used anti-malaria drug treatment on the Thailand-Myanmar border is linked to the increasing prevalence of specific mutations in the malaria parasite itself, according to a paper published in The Clinical infectious Disease Journal.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n20 April 2016
\n \n \n \nResults of the Wellcome Trust funded trial of the experimental anti-Ebola drug TKM-130803 have been published today in PLOS Medicine. Using a novel approach designed to get rapid indications of a drug's effectiveness, the trial showed that at the dose given the drug did not improve survival compared to historic controls.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n14 March 2016
\n \n \n \nDr Joel Tarning from MORU discusses his New England Journal of Medicine editorial on treating malaria in pregnancy, outlining new evidence on the effectiveness of artemisinin-combination therapies in pregnant women with malaria.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n11 February 2016
\n \n \n \nArtemisinins, the most effective antimalarials available, should be endorsed in the first trimester of pregnancy to ensure optimal treatment of falciparum malaria in pregnant women, reports a paper published today in The Lancet Infectious Diseases.
\n \n\n \n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n25 January 2016
\n \n \n \nResearchers from the Oxford University Clinical Research Unit in Vietnam have completed what is probably the largest ever controlled trial of tuberculous meningitis. The study is published in the New England Journal of Medicine.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n12 January 2016
\n \n \n \nMelioidosis, a difficult to diagnose deadly bacterial disease, is likely to be present in many more countries than previously thought, reports a paper published online today in the journal Nature Microbiology. The study predicts that melioidosis is present in 79 countries, including 34 that have never reported the disease.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n8 January 2016
\n \n \n \nThere are currently no effective treatments for Ebola, but blood plasma from people who have survived Ebola may be one potential treatment: this component of blood may contain antibodies that likely helped survivors successfully fight off the disease.
\n \n\n \n \n